1. Home
  2. UGRO vs TNXP Comparison

UGRO vs TNXP Comparison

Compare UGRO & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo urban-gro Inc.

UGRO

urban-gro Inc.

N/A

Current Price

$3.10

Market Cap

1.8M

ML Signal

N/A

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$13.40

Market Cap

220.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UGRO
TNXP
Founded
2014
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8M
220.5M
IPO Year
2018
2008

Fundamental Metrics

Financial Performance
Metric
UGRO
TNXP
Price
$3.10
$13.40
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$70.00
AVG Volume (30 Days)
70.2K
274.8K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,008,850.00
$10,094,000.00
Revenue This Year
$98.41
$7.00
Revenue Next Year
$23.34
$708.37
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.94
52 Week Low
$0.11
$13.07
52 Week High
$4.50
$69.65

Technical Indicators

Market Signals
Indicator
UGRO
TNXP
Relative Strength Index (RSI) 67.65 35.92
Support Level $0.28 N/A
Resistance Level $4.50 $20.36
Average True Range (ATR) 0.25 0.67
MACD -0.04 0.02
Stochastic Oscillator 76.49 16.33

Price Performance

Historical Comparison
UGRO
TNXP

About UGRO urban-gro Inc.

Urban-gro Inc operated as an integrated professional services and design-build firm offering architectural, engineering, and construction management solutions to the CEA, industrial, healthcare, and other commercial sectors. The company generated revenue by billing employees time on client projects and provided architectural, engineering, systems procurement and integration, and construction design-build solutions with a single point of accountability. For CEA clients, it developed indoor cultivation facilities for specialty crops, including cannabis and produce such as leafy greens, vegetables, herbs, and berries. Its segments included Equipment Systems (commercial horticulture equipment), Services (design-build services), and Construction Design-Build (general contracting).

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: